HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review
For HER2-positive metastatic breast cancer patients with the brain involved at initial diagnosis, there was no standard regimen before 2022 when the HER2CLIMB trial published its final overall survival analysis, and the prognosis is relatively poor under the current treatment strategy. We herein rep...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.980635/full |
| _version_ | 1797948111225618432 |
|---|---|
| author | Min-long Chen Wenjie Yu Binbin Cui Yijian Yu Zhaosheng Ma |
| author_facet | Min-long Chen Wenjie Yu Binbin Cui Yijian Yu Zhaosheng Ma |
| author_sort | Min-long Chen |
| collection | DOAJ |
| description | For HER2-positive metastatic breast cancer patients with the brain involved at initial diagnosis, there was no standard regimen before 2022 when the HER2CLIMB trial published its final overall survival analysis, and the prognosis is relatively poor under the current treatment strategy. We herein reported a case of a female patient who was initially diagnosed with HER2-positive metastatic breast cancer with brain metastases, receiving pyrotinib and trastuzumab-based systematic therapy after palliative craniocerebral radiotherapy as the first-line systematic therapy. During the treatment, the tumor lesions showed obvious regression, and chemotherapy drugs were gradually removed from the regimen. The patient continued receiving trastuzumab and pyrotinib for HER2-targeted therapy. She had achieved more than 26 months of progression-free survival and the disease was stable during the evaluation in April 2022. Radiotherapy followed by dual HER2-targeted therapy of macromolecular monoclonal antibodies trastuzumab and micromolecular TKI pyrotinib plus chemotherapy could be an alternative option for this subtype of patients and need to be further verified by future clinical trials. |
| first_indexed | 2024-04-10T21:38:18Z |
| format | Article |
| id | doaj.art-972886725c814b48af86ea6464c51a5e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T21:38:18Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-972886725c814b48af86ea6464c51a5e2023-01-19T08:53:43ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-01-011210.3389/fonc.2022.980635980635HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature reviewMin-long ChenWenjie YuBinbin CuiYijian YuZhaosheng MaFor HER2-positive metastatic breast cancer patients with the brain involved at initial diagnosis, there was no standard regimen before 2022 when the HER2CLIMB trial published its final overall survival analysis, and the prognosis is relatively poor under the current treatment strategy. We herein reported a case of a female patient who was initially diagnosed with HER2-positive metastatic breast cancer with brain metastases, receiving pyrotinib and trastuzumab-based systematic therapy after palliative craniocerebral radiotherapy as the first-line systematic therapy. During the treatment, the tumor lesions showed obvious regression, and chemotherapy drugs were gradually removed from the regimen. The patient continued receiving trastuzumab and pyrotinib for HER2-targeted therapy. She had achieved more than 26 months of progression-free survival and the disease was stable during the evaluation in April 2022. Radiotherapy followed by dual HER2-targeted therapy of macromolecular monoclonal antibodies trastuzumab and micromolecular TKI pyrotinib plus chemotherapy could be an alternative option for this subtype of patients and need to be further verified by future clinical trials.https://www.frontiersin.org/articles/10.3389/fonc.2022.980635/fullbreast cancerbrain metastasepyrotinibtrastuzumabtreatment |
| spellingShingle | Min-long Chen Wenjie Yu Binbin Cui Yijian Yu Zhaosheng Ma HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review Frontiers in Oncology breast cancer brain metastase pyrotinib trastuzumab treatment |
| title | HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review |
| title_full | HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review |
| title_fullStr | HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review |
| title_full_unstemmed | HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review |
| title_short | HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review |
| title_sort | her2 positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab based treatment a case report and literature review |
| topic | breast cancer brain metastase pyrotinib trastuzumab treatment |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.980635/full |
| work_keys_str_mv | AT minlongchen her2positivemetastaticbreastcancerwithbrainmetastasesrespondsfavorablytopyrotinibandtrastuzumabbasedtreatmentacasereportandliteraturereview AT wenjieyu her2positivemetastaticbreastcancerwithbrainmetastasesrespondsfavorablytopyrotinibandtrastuzumabbasedtreatmentacasereportandliteraturereview AT binbincui her2positivemetastaticbreastcancerwithbrainmetastasesrespondsfavorablytopyrotinibandtrastuzumabbasedtreatmentacasereportandliteraturereview AT yijianyu her2positivemetastaticbreastcancerwithbrainmetastasesrespondsfavorablytopyrotinibandtrastuzumabbasedtreatmentacasereportandliteraturereview AT zhaoshengma her2positivemetastaticbreastcancerwithbrainmetastasesrespondsfavorablytopyrotinibandtrastuzumabbasedtreatmentacasereportandliteraturereview |